Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan-Reference-Cited by-同舟云学术

Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan

Published:2022-07-01 Issue:7 Volume:45 Page:895-903
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Kashiwa Munenobu¹,Matsushita Ryo¹

Affiliation:

1. Department of Clinical Pharmacy and Healthcare Science, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/45/7/45_b22-00150/_pdf

Reference28 articles.

1. 1) Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram IBF. “Global cancer observatory: cancer today.” Lyon, Fr Int Agency Res Cancer.: ‹https://gco.iarc.fr/today›, accessed 16 April, 2022.

2. 2) Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 71, 209–249 (2021).

3. 3) Cancer Information Service, National Cancer Center, Japan. (Vital Statistics of Japan, Ministry of Health, Labour and Welfare). “Cancer Statistics.”: ‹https://ganjoho.jp/reg_stat/statistics/data/dl/index.html#a7›, accessed 16 April, 2022.

4. 4) Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 27 (suppl. 5), v38–v49 (2016).

5. 5) Kleinberg LR, Michael Korn W. Clinical practice guidelines in oncology NCCN categories of evidence and consensus. Vol. 14, JNCCN-Journal of the National Comprehensive Cancer Network. (2016), accessed 16 April, 2022.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group;Japanese Journal of Clinical Oncology;2024-08-24

2. Real‐world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients;Asia-Pacific Journal of Clinical Oncology;2024-04-29

3. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan;Journal of Gastroenterology;2023-09-19

4. Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis;Therapeutic Advances in Gastroenterology;2023-01